Mesalamine (Pentasa) is a specialized aminosalicylate commonly applied in clinical settings that involve inflammatory processes within the colon. This compound is primarily used for the treatment and maintenance of remission in patients with mildly to moderately active ulcerative colitis.

---

What Pentasa (Mesalamine) Treats: Main Uses and Benefits

The medication helps manage the chronic, recurring inflammation inherent to Ulcerative Colitis (UC), including localized forms like proctitis and proctosigmoiditis. The core therapeutic benefit supports the easing of internal swelling and irritation within the colon and rectum, which supports the goal of achieving and sustaining disease stability.

The treatment supports the management of symptom clusters that may become intense or disruptive, such as rectal bleeding, bloody diarrhea, abdominal pain, and the urgent, frequent need to use the restroom. By easing these challenging symptoms, the medication assists with maintaining functional stability during symptomatic phases. Furthermore, continued use may help reduce the likelihood of the return of inflammation, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Mesalamine is used when supportive symptom management is appropriate for the long term, acting as a key component of maintenance therapy after active symptoms subside.

Quick Fact: Relief for Inflammation-Driven Symptoms

---

Regulatory References

1. Official FDA Label via DailyMed

Who can and cannot use Pentasa (Mesalamine)?

Official regulatory information strictly defines the eligible patient population for Pentasa, primarily based on contraindications and the functional status of certain organ systems.

Eligibility scope

Classification	Population/Condition	Regulatory Basis
Contraindicated	Hypersensitivity to mesalamine, aminosalicylates, or salicylates (e.g., aspirin)	FDA, SmPC
Contraindicated	Severe liver and severe renal impairment	SmPC
Established Use	Adults with mildly to moderately active ulcerative colitis	FDA, SmPC
Not Recommended	Children 12 years of age and under	SmPC

Condition-specific Eligibility Rules

Use is subject to caution and special monitoring for several patient groups, as the active compound is substantially excreted by the kidney:

• Impaired Organ Function: Caution is required for patients with impaired renal function or impaired hepatic function. Renal function must be evaluated prior to and periodically during treatment [FDA, SmPC].
• Other Comorbidities: Caution is advised for patients with a history of allergy to sulfasalazine and those with pulmonary disease, particularly asthma [SmPC].

Age and Reproductive Status

• Pediatric Patients: Safety and efficacy have not been established in pediatric patients according to the US FDA label.
• Geriatric Patients: Caution is advised, as age-related factors, including changes in renal and hepatic function, must be taken into account [FDA, SmPC].
• Pregnancy and Lactation: Use is conditional and should occur only if clearly needed (pregnancy) or if the potential benefit outweighs the possible risks (lactation), as mesalamine is known to cross the placental barrier and is excreted in breast milk [FDA, SmPC].

The interaction profile for Mesalamine, the active component in Pentasa, is defined by specific drug combinations that present regulatory concern regarding increased toxicity risks or analytical interference. This profile is strictly based on official prescribing information provided by government health authorities.

Documented Pharmacodynamic and Exposure Interactions

Mesalamine co-administration with other medicines falls into two primary categories of officially documented interactions:

• Interactions with Purine Antagonists: The concurrent use of Mesalamine with immunosuppressants such as Azathioprine or 6-Mercaptopurine (and their derivative Thioguanine) can lead to an increase in the concentration of the active cytotoxic metabolite, 6-thioguanine nucleotide (6-TGN). This documented exposure modification raises the official risk for serious blood disorders, bone marrow failure, and associated complications.

• Interactions with Nephrotoxic Agents: Co-administration with other medicines known to be harmful to the kidneys, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), may result in a pharmacodynamic interaction that increases the overall potential for nephrotoxicity (kidney damage).

Procedural and Analytical Constraints

Mesalamine use is officially documented to cause interference during specific medical procedures. The main metabolite of Mesalamine, N-acetyl-5-aminosalicylic acid, may lead to spuriously elevated test results when measuring urinary normetanephrine via liquid chromatography with electrochemical detection. No mandatory separation of administration timing is officially required, nor are interactions with food, alcohol, or herbal products specifically documented in the primary regulatory labels.

The mechanism of action for Mesalamine (5-ASA) involves highly localized and multifaceted mechanistic activity directed at inflammatory pathways within the lining of the colon and distal small intestine. The compound functions by interfering with several distinct biochemical pathways to modulate pro-inflammatory signaling at the site of tissue involvement.

Dual Inhibition of Inflammatory Enzymes

Mesalamine acts as a localized inhibitor of key lipid-metabolizing enzymes: Cyclooxygenase (COX) and Lipoxygenase (LOX). By blocking these pathways, the drug suppresses the synthesis of pro-inflammatory mediators like prostaglandins and leukotrienes, which are mediators of local vasodilation and tissue fluid accumulation. This action results in a reduced infiltration of fluid and immune cells into the bowel wall, attenuating the processes that lead to tissue fluid accumulation.

Modulation of Gene-Level Signaling

The drug interferes with the activation of Nuclear factor-kappa B ( NF-kappa B), a transcription factor essential for manufacturing inflammatory proteins inside the cells. This suppression alters the release of pro-inflammatory cytokines and chemokines, resulting in a reduced recruitment and infiltration of immune cells like neutrophils into the intestinal wall.

Scavenging Reactive Oxygen Species

Mesalamine utilizes its antioxidant properties to directly neutralize Reactive Oxygen Species (ROS) and free radicals that are generated in abundance by active immune cells. This scavenging action mitigates the oxidative damage to intestinal epithelial cells, thereby influencing the maintenance of mucosal barrier integrity.

Pentasa extended-release capsules are taken orally and are used for the induction of remission and symptomatic treatment of mildly to moderately active ulcerative colitis in adults. Always follow the precise dosing regimen and treatment duration prescribed by your healthcare provider; do not stop treatment without consultation.

Administration Instructions

Instruction	Detail
Swallow	Swallow the capsule(s) whole. Do not crush, chew, or break them, as this can affect the controlled-release properties of the medication.
Alternative Method	If you have difficulty swallowing the capsules whole, you may open the capsule(s) and sprinkle the entire contents onto a spoonful of applesauce or yogurt. This mixture must be consumed immediately, without chewing the contents.
Dosing	The recommended dosage for the induction of remission in adults is typically 1 g (four 250 mg capsules or two 500 mg capsules) administered orally four times daily. This results in a total daily dose of 4 g.

Important Considerations

• Hydration: It is important to drink an adequate amount of fluids throughout your treatment with Pentasa.
• Renal Function: Your doctor will evaluate your renal function (kidney function) before you begin treatment and periodically while you are taking Pentasa.
• Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time.

Research Evidence / Overview of Studies for Pentasa (Mesalamine)

This overview describes the types of clinical studies that have been conducted on Mesalamine (Pentasa), outlining how studies were conducted and what patterns were observed in the research, according to regulatory and scientific evidence. The goal is to provide context about the available research without offering personal medical advice or directions on how to use the medicine.

---

Evidence for Use in Mild-to-Moderately Active Ulcerative Colitis

Research exploring the use of Mesalamine during periods of increased symptom activity in ulcerative colitis (UC) has primarily relied on short-term Randomized Controlled Trials (RCTs). These studies were designed to evaluate the agent against a placebo (an inactive substance) and were also examined alongside other aminosalicylate preparations. Researchers focused on clinical outcomes (such as changes in bowel movement frequency) and endoscopic outcomes (assessment of inflammation) over typical intervals of 6 to 12 weeks.

Findings describe patterns observed in these trials where tracked measurements of clinical and endoscopic remission were reported in study participants. Results apply only to the specific populations studied, and comparative evidence is lacking from long-term, head-to-head trials against certain other aminosalicylate preparations.

Evidence for Use in Maintaining Ulcerative Colitis Remission

For patients whose UC is stable, research has focused on outcomes related to sustaining disease stability, primarily through long-term RCTs. Studies monitored the rate of relapse or flare-up frequency as the main outcome, tracking how often symptoms returned over time intervals like 6 to 12 months. Data show patterns related to the frequency of relapse events being observed differently between the groups receiving Mesalamine and the groups receiving the inactive substance.

Evidence in Specific Patient Groups and Remaining Uncertainty

Mesalamine was evaluated in clinical research involving children and adolescents (typically ages 5 to 17) who had mildly to moderately active UC. These studies explored symptom changes and endoscopic measurements in this younger population. However, data for certain groups remain insufficient; for instance, comparative evidence in older adults with multiple health issues (comorbidities) is limited. Furthermore, the certainty remains low regarding the ideal duration for ongoing therapy for those who have been symptom-free for multiple years.

Common questions about Pentasa (Mesalamine) (FAQ)

Q: What is Pentasa (Mesalamine) used for?

Pentasa is a brand name for the medication mesalamine (also known as mesalazine). It belongs to a class of drugs called aminosalicylates. It is primarily used to treat and manage ulcerative colitis (UC), a type of inflammatory bowel disease (IBD). It helps to reduce inflammation in the lining of the colon, which can ease symptoms like diarrhea, rectal bleeding, and abdominal pain.

---

Q: How does Pentasa (Mesalamine) work?

Mesalamine is thought to work by acting directly on the lining of the inflamed intestine. It is believed to block certain substances in the body, called prostaglandins, that contribute to inflammation. Pentasa's formulation is designed to release the medication slowly throughout the entire digestive tract, from the small intestine to the colon, to target the inflammation.

---

Q: Can I stop taking Pentasa (Mesalamine) if I feel better?

You should not stop taking Mesalamine suddenly without consulting a healthcare professional. For many people with ulcerative colitis, this medication is used as a maintenance therapy to help keep the disease in remission and prevent flare-ups. Stopping the medication prematurely, even if symptoms improve, may increase the risk of your ulcerative colitis returning or worsening.

---

Q: What are the common side effects of Pentasa (Mesalamine)?

Common side effects can include:

• Headache
• Nausea or vomiting
• Abdominal pain, gas, or cramping
• Diarrhea
• Influenza-like syndrome (fever, chills, body aches)

Serious side effects are less common and should be reported to a healthcare provider immediately. These may include signs of kidney problems or a severe reaction called mesalamine-induced acute intolerance syndrome.

How to Store and Dispose of Pentasa (Mesalamine)?

Official regulatory guidelines define specific conditions to maintain the stability and safety of Pentasa (mesalamine). Storage requirements vary slightly by formulation, but all are mandated by governmental labeling.

Storage Conditions and Requirements

Condition Type	Requirement
Temperature	Store capsules at Controlled Room Temperature (20 C to 25 C). Tablets must be stored below 30 C.
Environmental	The product must not be frozen and must be stored in the original package to protect from light.
Child Safety	The medication must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Pentasa product or associated waste material must be disposed of strictly in accordance with local requirements for pharmaceutical waste handling.